Pfizer (PFE, Financial) has received approval from the U.S. Food and Drug Administration for its new medication, Hympavzi, aimed at treating a rare bleeding disorder. This drug is administered via an auto-injector pen, delivering it under the skin to prevent or reduce bleeding in patients aged 12 and older with hemophilia A or B.
Hympavzi is Pfizer's second hemophilia treatment to gain FDA approval this year, following the approval of its hemophilia B gene therapy, Beqvez, in April. Analysts from LSEG project that Hympavzi could generate $300 million in sales by 2030.
